ZYME Zymeworks Inc.

51.47
-1.39  -3%
Previous Close 52.86
Open 53.42
52 Week Low 20.33
52 Week High 59.03
Market Cap $2,364,836,142
Shares 39,309,157
Float 45,579,241
Enterprise Value $1,964,825,961
Volume 572,530
Av. Daily Volume 426,205
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ZW49
HER2-Expressing Cancers
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Zanidatamab (ZW25)
HER2-expressing Gastroesophageal Adenocarcinoma
Phase 1
Phase 1
Phase 1 data presented at ASCO Gastrointestinal Cancers Symposium, January 15, 2021. Objective response rate (ORR) was 39% (13/33). Phase 2 trial ongoing.
Zanidatamab (ZW25)
HER2-amplified biliary tract cancers
Phase 1/2
Phase 1/2
Phase 2 trial has commenced enrollment. Updated Phase 1 data at ASCO GI January 15, 2021 - objective response rate (ORR) in trastuzumab-naïve patients was 47%.
Zanidatamab (ZW25) + Chemotherapy + Tislelizumab
Breast Cancer / Gastric Cancer / Gastroesophageal Junction Cancer
Phase 1/2
Phase 1/2
Phase 1/2 trial ongoing.
ZW25 + chemo
HER2-expressing cancers
Phase 1
Phase 1
Phase 1 trial is ongoing.
ZW25 and Ibrance
HER2-positive, HR-positive breast cancer
Phase 2
Phase 2
Phase 2 initiation announced January 12, 2020.

Latest News

    • Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers
    • Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical data for the HER2‑targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA). The data are being presented today at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually January 15 – 17, 2021.

    This press release features multimedia…

    • Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers
    • Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical data for the HER2‑targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA). The data are being presented today at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually January 15 – 17, 2021.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210115005163/en/

    "Data presented today at ASCO GI continue to demonstrate the potential of zanidatamab in advanced HER2-expressing cancers with high unmet need. The response rates and median duration of response in refractory BTC and GEA compare favorably to current standard of care and emerging treatments," said Diana Hausman, M.D., Chief Medical Officer at Zymeworks. "The BTC data were the basis of the recent Breakthrough Therapy designation granted by the FDA, a key step in helping zanidatamab become the first potential HER2‑targeted therapy approved in this indication. Furthermore, the activity in GEA supports our goal of establishing zanidatamab as the foundational HER2-targeted therapy for GEA and other HER2-positive cancers, not only in later stage disease, but also in earlier lines of treatment."

    The following presentations are available to conference registrants on the ASCO conference website as well as to the general public at ir.zymeworks.com/events-and-presentations/.

    Zanidatamab Monotherapy and Chemotherapy Combinations in HER2-Expressing Gastroesophageal Cancer – Clinical Results – Abstract #164

    Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a Phase 1 study (Presenter: Funda Meric-Bernstam, MD, UT MD Anderson Cancer Center, TX; Rapid Abstract oral presentation on Friday, January 15, 11:30 am-12:15 pm ET)

    HER2 is overexpressed in approximately 20% of GEA patients. For these patients, trastuzumab in combination with chemotherapy is the only approved HER2‑targeted therapy. Treatment options are currently limited if disease progression occurs after trastuzumab in combination with chemotherapy.

    Findings from an ongoing Phase 1 study of zanidatamab in HER2-positive GEA were last presented in July 2020. New and updated results are being presented in a Rapid Abstract oral presentation today, January 15th, at 11:30 am ET at the ASCO Gastrointestinal Cancers Symposium followed by a webcast at 5:00 pm ET to discuss the data, led by zanidatamab study investigator Dr. Funda Meric-Bernstam, MD.

    The data being reported are from HER2-expressing GEA patients who received zanidatamab either as monotherapy (n=35) or in combination with chemotherapies (n=28). The groups had a median of two to three (range 0-7) prior therapies, with a high percentage (88-91%) having received prior HER2-targeted therapies. The data continue to demonstrate that zanidatamab is well tolerated with the majority of treatment-related AEs considered mild to moderate in severity (Grade 1 or 2) and manageable in the outpatient setting.

    In 33 response-evaluable patients who received zanidatamab as monotherapy (10 mg/kg weekly or 20 mg/kg every two weeks), the objective response rate (ORR) was 39% (13/33), 11 (33%) of which were confirmed by a subsequent scan. The disease control rate (DCR) was 61% (20/33) and median duration of response (DOR) was six months.

    In 10 response-evaluable patients who received zanidatamab (20 mg/kg every two weeks) plus paclitaxel, the ORR was 60% (6/10), five (50%) of which were confirmed by a subsequent scan including one patient who experienced a complete response. The DCR was 90% (9/10) for this group. In 14 response-evaluable patients who received zanidatamab (20 mg/kg every two weeks or 30 mg/kg every three weeks) plus capecitabine, the confirmed ORR was 57% (8/14) and the DCR was 71% (10/14). Overall the median DOR for zanidatamab plus chemotherapy was 8.9 months and the median progression-free survival (PFS) was 5.6 months with eight (29%) patients still on study at the time of data cut-off.

    In 2019, Zymeworks initiated a global, multicenter Phase 2 clinical trial (NCT03929666) evaluating zanidatamab in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic GEA. Taken together, data from the Phase 1 and Phase 2 studies further support the company's plans to initiate, with partner BeiGene, a pivotal study for zanidatamab plus chemotherapy +/- tislelizumab (anti-PD1), as first-line treatment for advanced HER2-positive GEA in mid-2021.

    Zanidatamab Monotherapy in HER2-Amplified Biliary Tract Cancer – Clinical Results – Abstract #299

    Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a Phase 1 study (Presenter: Funda Meric-Bernstam, MD, UT MD Anderson Cancer Center, TX)

    Globally, more than 210,000 people are diagnosed with BTC every year and as many as one-fifth of these patients have tumors that express HER2. Currently no HER2‑targeted therapy has been approved for the treatment of BTC.

    Findings from the ongoing Phase 1 study of zanidatamab in HER2-amplified BTC were last shared in July 2020. The updated and new results are being presented today in a poster session at the ASCO Gastrointestinal Cancers Symposium.

    Data were reported on 21 patients diagnosed with HER2-amplified BTC who received zanidatamab at the recommended dose of 20 mg/kg every two weeks. Patients received a median of two (range 1-8) prior therapies and five (24%) of the patients were previously treated with the HER2-targeted therapy trastuzumab.

    Zanidatamab was well tolerated and demonstrated durable antitumor activity in these patients. All zanidatamab-related adverse events (AEs) were mild or moderate in severity (Grade 1 or 2). The confirmed objective response rate (ORR) in trastuzumab-naïve patients was 47% (7/15) and overall ORR was 40% (8/20). The overall disease control rate (DCR) was 65% (13/20), and median duration of response (DOR) was 7.4 months with several patients still on study at the time of data cut-off.

    Based on these results, in July 2020 Zymeworks initiated a global pivotal Phase 2b trial (HERIZON-BTC-01; ZW25-203) [NCT04466891] of zanidatamab monotherapy in patients with HER2-amplified BTC that has been previously treated with at least one gemcitabine-containing systemic chemotherapy regimen. The US Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation for zanidatamab in patients with previously treated HER2 gene-amplified BTC, based on evaluation of the Phase 1 data. This global pivotal Phase 2 study of zanidatamab in BTC may enable the submission of a Biologics License Application by Zymeworks in the United States as early as 2022.

    Zanidatamab HERIZON-BTC-01 Trial in Progress Poster Presented Today – Abstract TPS352

    A Phase 2b, Open-label, Single-arm Study of Zanidatamab (ZW25) Monotherapy in Patients with Advanced or Metastatic HER2-amplified Biliary Tract Cancers (BTC): HERIZON-BTC-01 Study (Lead Author: Shubham Pant, MD, UT MD Anderson Cancer Center, TX)

    Zymeworks is presenting a trial in progress poster at ASCO GI for a global pivotal Phase 2 trial in HER2-amplified BTC (HERIZON-BTC-01; ZW25-03). Multiple clinical sites are now open to enrollment in the U.S., South Korea, Italy and Spain, with additional sites planned in Canada, Chile, China, France and the UK [Phase 2:NCT04466891]. This study is designed to support accelerated approval based on a primary endpoint of objective response rate, and key secondary endpoints of duration of response and safety.

    About the Zanidatamab Phase 1 Clinical Trial

    Zymeworks' Phase 1 zanidatamab study has three parts. From part one of the study (the dose-escalation phase), the recommended single-agent dose was determined to be 20 mg/kg once every two weeks or 10 mg/kg weekly. In the second part of the study (the cohort expansion phase), additional patients are being enrolled to further assess zanidatamab's single-agent tolerability and antitumor activity against a variety of cancer types in different settings. The third part of the study (the combination phase) is underway and evaluating zanidatamab in combination with selected chemotherapy agents in gastroesophageal and breast cancer patients with HER2 high or lower HER2 expression levels.

    About Zanidatamab

    Zanidatamab is a bispecific antibody, based on Zymeworks' Azymetric™ platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. This unique design results in multiple mechanisms of action including dual HER2 signal blockade, increased binding, and removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The FDA has granted Breakthrough Therapy designation for zanidatamab in patients with previously treated HER2 gene-amplified BTC, and two Fast Track designations to zanidatamab, one as a single agent for refractory BTC and one in combination with standard of care chemotherapy, for first-line gastroesophageal adenocarcinoma (GEA). These designations mean zanidatamab is eligible for Accelerated Approval, Priority Review and Rolling Review, as well as intensive FDA guidance on an efficient drug development program. Zanidatamab has also received Orphan Drug designations for the treatment of biliary tract, gastric and ovarian cancers, as well as Orphan Drug designation for the treatment of gastric cancer from the European Medicines Agency.

    About Zymeworks Inc.

    Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

    Zymeworks Cautionary Note Regarding Zymeworks' Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this news release include statements that relate to the potential of zanidatamab in advanced HER2-expressing cancers with high unmet need, Zymeworks' global pivotal trial for zanidatamab in BTC (including the potential submission of a BLA), Zymeworks' plans to launch a second pivotal trial with BeiGene, and other information that is not historical information. When used herein, words such as "may", "plan", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions, including assumptions regarding anticipated reporting of additional clinical and preclinical data, the efficacy of zanidatamab, ZW49, and Zymeworks' therapeutic platforms, and Zymeworks' ability to maintain its partnership arrangements. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the factors described under "Risk Factors" in Zymeworks' Quarterly Report on Form 10-Q for its fiscal quarter ended September 30, 2020 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Consequently, forward-looking statements should be regarded solely as Zymeworks' current plans, estimates, and beliefs. You should not place undue reliance on forward-looking statements. Zymeworks cannot guarantee future results, events, levels of activity, performance, or achievements. Zymeworks does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances, or to reflect the occurrences of unanticipated events, except as may be required by law.

    View Full Article Hide Full Article
  1. Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities.

    "2020 was a leap forward for our lead clinical program in terms of a potential first approval and future approvals," said Ali Tehrani, Ph.D., President and CEO at Zymeworks. "The launch of our first pivotal trial and achievement of Breakthrough Therapy designation for zanidatamab mark important milestones towards our accelerated commercialization strategy, and our new clinical partnerships further strengthen zanidatamab's broad therapeutic profile. 2021 promises to be a data-rich year for both zanidatamab and ZW49 as we continue to demonstrate…

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities.

    "2020 was a leap forward for our lead clinical program in terms of a potential first approval and future approvals," said Ali Tehrani, Ph.D., President and CEO at Zymeworks. "The launch of our first pivotal trial and achievement of Breakthrough Therapy designation for zanidatamab mark important milestones towards our accelerated commercialization strategy, and our new clinical partnerships further strengthen zanidatamab's broad therapeutic profile. 2021 promises to be a data-rich year for both zanidatamab and ZW49 as we continue to demonstrate their potential to become foundational therapies in the treatment of HER2-expressing cancers."

    2020 Achievements

    Zanidatamab Enters Late-Stage Clinical Development with Accelerated Strategy

    • Zymeworks initiated a global pivotal trial (HERIZON-BTC-01) for zanidatamab monotherapy in patients with previously treated HER2 gene-amplified biliary tract cancer (BTC). This single arm trial is designed to support accelerated approval based on a primary endpoint of objective response rate and may enable submission of a Biologics License Application (BLA) as early as 2022.
    • Zanidatamab received additional drug review special designations in the U.S. and the European Union. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for BTC and the European Commission (EC) granted Orphan Drug designation for gastroesophageal adenocarcinoma (GEA), expediting potential commercialization. Previously the FDA granted two Fast Track designations to zanidatamab, in BTC and GEA, in addition to Orphan Drug designations for BTC, GEA, and ovarian cancer.

    Zanidatamab Data and Partnerships Continue to Support Broad Therapeutic Potential

    • Gastric Cancer: Clinical data from patients with refractory GEA treated with zanidatamab monotherapy as well as zanidatamab in combination with chemotherapy were updated and support plans to launch a second pivotal trial as 1st line treatment for advanced HER2-positive GEA in mid-2021 with partner BeiGene. These data will be updated as part of an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 15, 2021.
    • Breast Cancer: Clinical collaborations were initiated to evaluate zanidatamab in combination with a CD47 blocker (ALX Oncology's ALX148) in patients with advanced HER2‑expressing breast cancer and with a CDK4/6 inhibitor (Pfizer's Ibrance) in patients with HER2‑positive, HR-positive breast cancer.
    • Endometrial Cancer: Zymeworks' first investigator-led trial was initiated by Dr. Vicky Makker at Memorial Sloan Kettering Cancer Center. The Phase 2 trial will evaluate zanidatamab monotherapy in HER2-overexpressed advanced endometrial cancers and carcinosarcomas.

    Clinical Advancement of HER2 Bispecific ADC, ZW49, for HER2 Expressing Cancers

    • ZW49 is being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents. Clinical studies continued in 2020 with dose escalation to determine the safety and efficacy profile of ZW49. Zymeworks will be providing a clinical progress update for ZW49 by webcast on Wednesday, January 27, 2021 at 4:30 pm ET.

    Commercial, Clinical and Scientific Competencies Added to Leadership Team

    • Zymeworks welcomed key commercial, scientific and clinical development talent to the leadership team with the additions of Guowei Fang, Ph.D., as Senior Vice President, Research, James Priour as Senior Vice President, Commercial, Manny Duenas as Vice President, Global Value and Access, and Pamela Farmer, MD, as Vice President, Global Patient Safety.

    Partnerships Advance: Milestone Payments Received and Deal Values Increase

    • Our partnerships continued to advance in 2020 with Iconic/Exelixis achieving a milestone for ZymeLink™ together with new and expanded Azymetric™ and EFECT™ collaborations with Merck and BMS. Zymeworks has nine active collaborations that could result in up to US$8.6 billion in potential milestone payments in addition to royalties on potential product sales.

    Balance Sheet Strengthened and Cash Runway Extended

    • In early 2020, Zymeworks completed an oversubscribed public financing raising US$320.8 million, extending its runway into 2022 and potentially beyond. The Company also received non-dilutive capital from several of its pharmaceutical partners.

    Updated Corporate Priorities

    • Complete enrolment of zanidatamab pivotal trial in HER2+ biliary tract cancer
    • Launch pivotal trial in 1st line HER2+ GEA and present supporting Phase 2 clinical data
    • Present data to support zanidatamab breast cancer development strategy
    • Advance ZW49 into and complete cohort expansion
    • Present data from new therapeutic programs and technology platforms

    About Zymeworks Inc.

    Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2+ biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

    Zymeworks Cautionary Note Regarding Zymeworks' Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this news release include statements that relate to Zymeworks' global pivotal trial for zanidatamab in BTC (including the potential submission of a BLA), commercialization strategy, anticipated updates for zanidatamab and ZW49 and their potential to become foundational therapies in the treatment of HER2-expressing cancers, plans to launch a second pivotal trial with BeiGene, potential milestone payments and royalties on potential product sales, anticipated cash runway, and other information that is not historical information. When used herein, words such as "may", "will", "plan", "continue", "potential", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions, including assumptions regarding anticipated reporting of additional clinical and preclinical data, the efficacy of ZW25, ZW49, and Zymeworks' therapeutic platforms, and Zymeworks' ability to enter into new partnership arrangements. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the factors described under "Risk Factors" in Zymeworks' Quarterly Report on Form 10-Q for its fiscal quarter ended September 30, 2020 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Consequently, forward-looking statements should be regarded solely as Zymeworks' current plans, estimates, and beliefs. You should not place undue reliance on forward-looking statements. Zymeworks cannot guarantee future results, events, levels of activity, performance, or achievements. Zymeworks does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances, or to reflect the occurrences of unanticipated events, except as may be required by law.

    View Full Article Hide Full Article
  2. Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference. In addition, Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and provide an update on ZW49's clinical progress.

    J.P. Morgan Healthcare Conference Presentation

    The J.P. Morgan presentation will take place on Monday, January 11, 2021 at 3:40 p.m. ET.

    Zanidatamab ASCO GI Webcast

    Zymeworks will host a webcast on Friday, January 15, 2021 at 5:00 pm ET to discuss the clinical results for…

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference. In addition, Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and provide an update on ZW49's clinical progress.

    J.P. Morgan Healthcare Conference Presentation

    The J.P. Morgan presentation will take place on Monday, January 11, 2021 at 3:40 p.m. ET.

    Zanidatamab ASCO GI Webcast

    Zymeworks will host a webcast on Friday, January 15, 2021 at 5:00 pm ET to discuss the clinical results for the Company's HER2 bispecific, zanidatamab, in biliary tract cancer and gastroesophageal cancer presented at ASCO GI earlier that day. The data will be discussed by lead investigator, Dr. Funda Meric-Bernstam, M.D., Clinical Investigator and Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

    ZW49 Clinical Update Webcast

    Zymeworks will host a webcast on Wednesday, January 27, 2021 at 4:30 pm ET to provide an update on clinical progress from the Phase 1 dose-escalation study for the Company's HER2 bispecific antibody-drug conjugate, ZW49.

    Interested parties can access these live webcasts via a link from Zymeworks' website at http://ir.zymeworks.com/events-and-presentations. Participants are encouraged to connect five to ten minutes prior to the scheduled start time. A recorded replay will also be available on the website shortly after the webcast concludes.

    About Zymeworks Inc.

    Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a registration-enabling clinical trial for refractory HER2+ biliary tract cancer as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

    View Full Article Hide Full Article
  3. VICTORIA, BC, Dec. 11, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATD) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into a research collaboration with the National Research Council of Canada's (NRC) Human Health Therapeutics (HHT) Research Centre to develop its neutralizing PolyTope™ antibodies against SARS-CoV-2.

    IPA is also considering acquiring a license for the NRC CHO cell-based rapid expression platform to be used in pre-clinical and clinical manufacturing of their lead monoclonal antibodies. Researchers from the NRC's HHT Research Centre will deploy the CHO-based expression platform to accelerate the identification and development of IPA's lead antibody candidates.

    The NRC is supporting this research through the Pandemic Response Challenge Program (PRCP) and the Industrial Research Assistance Program (IRAP). The project is also in collaboration with Zymeworks Inc. (NYSE:ZYME) for the design and development of IPA's lead antibody candidates. ImmunoPrecise identified antibodies directed against the SARS-CoV-2 virus spike protein during the summer of 2020 by screening tens of thousands of antibodies from multiple sources and converging upon a panel of candidates that showed in vitro functional activity and synergistic effects in pseudovirus-based neutralization assays. Top neutralizing antibodies have been progressed for preclinical testing in the PolyTope™ Therapy program.

    IPA considers the NRC to be a partner of choice to develop and manufacture their antibody therapeutics, as the NRC is uniquely positioned in Canada to address the various facets of this project having integrated, multi-disciplinary biologics research facilities based in Montréal and Ottawa.

    "IPA is pleased to contribute to this Canadian endeavor with the NRC and Zymeworks," stated Jennifer Bath, CEO of ImmunoPrecise. "IPA is proud to embark on its first collaboration with the NRC, as we continue to establish ourselves as a key player in the Canadian life science ecosystem and in the current pandemic. We believe this partnership between the NRC (HHT, PRCP and IRAP) and Zymeworks to have tremendous potential to generate best-in-class SARS-CoV-2 therapeutics within this expert and motivated team environment in Canada."

    About ImmunoPrecise Antibodies Ltd.

    ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company's experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise's full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact .

    About IPA's SARS Polytope™ Therapies

    Monoclonal antibodies were derived from several animal species, including humans, llama, rabbits and transgenic OmniAb® (humanized) animals to access a broad epitope coverage. IPA exploits multiple antibody formats, valency, and size to select antibodies against multiple/rare epitopes. In a global effort involving its scientists in North America and Europe, IPA has now developed a rich and diverse discovery portfolio of SARS-CoV-2 candidate antibodies yielding epitope and functional diversity.

    Forward Looking Information

    This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend", "should" and similar expressions to identify forward-looking statements and include the Company's beliefs with respect to the potential for its antibodies or vaccines to be further developed or approved to treat or protect against COVID-19 (or SARS-CoV-2) or to complete any transactions with respect to those antibodies. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the previous quarter ended July31st, 2020 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/immunoprecise-collaboration-enables-preclinical-manufacturing-of-lead-antibodies-targeting-sars-cov-2-301191080.html

    SOURCE ImmunoPrecise Antibodies Ltd.

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2020/11/c8992.html

    View Full Article Hide Full Article
  4. VICTORIA, BC, Dec. 11, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATD) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into a research collaboration with the National Research Council of Canada's (NRC) Human Health Therapeutics (HHT) Research Centre to develop its neutralizing PolyTope™ antibodies against SARS-CoV-2.

    IPA is also considering acquiring a license for the NRC CHO cell-based rapid expression platform to be used in pre-clinical and clinical manufacturing of their lead monoclonal antibodies. Researchers from the NRC's HHT Research Centre will deploy the CHO-based expression platform to accelerate the identification…

    VICTORIA, BC, Dec. 11, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATD) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into a research collaboration with the National Research Council of Canada's (NRC) Human Health Therapeutics (HHT) Research Centre to develop its neutralizing PolyTope™ antibodies against SARS-CoV-2.

    IPA is also considering acquiring a license for the NRC CHO cell-based rapid expression platform to be used in pre-clinical and clinical manufacturing of their lead monoclonal antibodies. Researchers from the NRC's HHT Research Centre will deploy the CHO-based expression platform to accelerate the identification and development of IPA's lead antibody candidates.

    The NRC is supporting this research through the Pandemic Response Challenge Program (PRCP) and the Industrial Research Assistance Program (IRAP). The project is also in collaboration with Zymeworks Inc. (NYSE:ZYME) for the design and development of IPA's lead antibody candidates. ImmunoPrecise identified antibodies directed against the SARS-CoV-2 virus spike protein during the summer of 2020 by screening tens of thousands of antibodies from multiple sources and converging upon a panel of candidates that showed in vitro functional activity and synergistic effects in pseudovirus-based neutralization assays. Top neutralizing antibodies have been progressed for preclinical testing in the PolyTope™ Therapy program.

    IPA considers the NRC to be a partner of choice to develop and manufacture their antibody therapeutics, as the NRC is uniquely positioned in Canada to address the various facets of this project having integrated, multi-disciplinary biologics research facilities based in Montréal and Ottawa.

    "IPA is pleased to contribute to this Canadian endeavor with the NRC and Zymeworks," stated Jennifer Bath, CEO of ImmunoPrecise. "IPA is proud to embark on its first collaboration with the NRC, as we continue to establish ourselves as a key player in the Canadian life science ecosystem and in the current pandemic. We believe this partnership between the NRC (HHT, PRCP and IRAP) and Zymeworks to have tremendous potential to generate best-in-class SARS-CoV-2 therapeutics within this expert and motivated team environment in Canada."

    About ImmunoPrecise Antibodies Ltd.

    ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company's experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise's full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact .

    About IPA's SARS Polytope™ Therapies

    Monoclonal antibodies were derived from several animal species, including humans, llama, rabbits and transgenic OmniAb® (humanized) animals to access a broad epitope coverage. IPA exploits multiple antibody formats, valency, and size to select antibodies against multiple/rare epitopes. In a global effort involving its scientists in North America and Europe, IPA has now developed a rich and diverse discovery portfolio of SARS-CoV-2 candidate antibodies yielding epitope and functional diversity.

    Forward Looking Information

    This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend", "should" and similar expressions to identify forward-looking statements and include the Company's beliefs with respect to the potential for its antibodies or vaccines to be further developed or approved to treat or protect against COVID-19 (or SARS-CoV-2) or to complete any transactions with respect to those antibodies. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the previous quarter ended July31st, 2020 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/immunoprecise-collaboration-enables-preclinical-manufacturing-of-lead-antibodies-targeting-sars-cov-2-301191080.html

    SOURCE ImmunoPrecise Antibodies Ltd.

    View Full Article Hide Full Article
View All Zymeworks Inc. News